Zai Lab Limited and Novocure have released an update on their phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in the fourth stage non-small cell lung cancer (NSCLC). FREMONT, CA: Zai Lab Limited and Novocure have released an update on their phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in the fourth stage non-small cell lung cancer (NSCLC) after platinum failure. Following a regular evaluation of the study by an independent data monitoring committee (DMC), Novocure was notified that the pre-specified interim analysis for the LUNAR trial would be accelerated given the length of accrual and the number of events observed to date. The interim study looked at data from 210 patients who had enrolled in the LUNAR trial throughout February 2021.